Literature DB >> 33488152

Synthesis, cytotoxic assessment, and molecular docking studies of 2,6-diaryl-substituted pyridine and 3,4- dihydropyrimidine-2(1H)-one scaffolds.

Zahra Hosseinzadeh1, Nima Razzaghi-Asl2, Ali Ramazani1,4, Hamideh Aghahosseini1,4, Ali Ramazani1,4.   

Abstract

Cancer is one of the main global health problems. In order to develop novel antitumor agents, we synthesized 3,4-dihydropyrimidine-2(1H)-one (DHPM) and 2,6-diaryl-substituted pyridine derivatives as potential antitumor structures and evaluated their cytotoxic effects against several cancer cell lines. An easy and convenient method is reported for the synthesis of these derivatives, employing cobalt ferrite (CoFe 2 O 4 @SiO 2 -SO 3 H) magnetic nanoparticles under microwave irradiation and solvent-free conditions. The structural characteristics of the prepared nanocatalyst were investigated by FTIR, XRD, SEM, and TGA techniques. In vitro cytotoxic effects of the synthesized products were assessed against the human breast adenocarcinoma cell line (MCF-7), gastric adenocarcinoma (AGS), and human embryonic kidney (HEK293) cells via MTT assay. The results indicated that compound 4r (DHPM derivative) was the most toxic molecule against the MCF-7 cell line (IC 50 of 0.17 μg/mL). Moreover, compounds 4j and 4r (DHPM derivatives) showed excellent cytotoxic activities against the AGS cell line, with an IC 50 of 4.90 and 4.97 μg/mL, respectively. Although they are pyridine derivatives, compounds 5g and 5m were more active against the MCF-7 cell line. Results showed that the candidate compounds exhibited low cytotoxicity against HEK293 cells. The kinesin Eg5 inhibitory potential of the candidate compounds was evaluated by molecular docking. The docking results showed that, among the pyridine derivatives, compound 5m had the most free energy of binding (-9.52 kcal/mol) and lowest Ki (0.105 μM), and among the pyrimidine derivatives, compound 4r had the most free energy of binding (-7.67 kcal/mol) and lowest Ki (2.39 μM). Ligand-enzyme affinity maps showed that compounds 4r and 5m had the potential to interact with the Eg5 binding site via H-bond interactions to GLU116 and GLY117 residues. The results of our study strongly suggest that DHPM and pyridine derivatives inhibit important tumorigenic features of breast and gastric cancer cells. Our results may be helpful in the further design of DHPMs and pyridine derivatives as potential anticancer agents.
Copyright © 2020 The Author(s).

Entities:  

Keywords:  Cancer; cytotoxicity; kinesin Eg5; magnetic nanocatalyst; pyridine; pyrimidinone

Year:  2020        PMID: 33488152      PMCID: PMC7751820          DOI: 10.3906/kim-1903-72

Source DB:  PubMed          Journal:  Turk J Chem        ISSN: 1300-0527            Impact factor:   1.239


  30 in total

1.  Synthesis and anti-tumor activity of 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives in vitro.

Authors:  Fan Zhang; Yanfang Zhao; Li Sun; Lu Ding; Yucheng Gu; Ping Gong
Journal:  Eur J Med Chem       Date:  2011-04-03       Impact factor: 6.514

2.  Novel one-pot, four-component condensation reaction: an efficient approach for the synthesis of 2,5-disubstituted 1,3,4-oxadiazole derivatives by a Ugi-4CR/aza-Wittig sequence.

Authors:  Ali Ramazani; Aram Rezaei
Journal:  Org Lett       Date:  2010-06-18       Impact factor: 6.005

3.  Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core.

Authors:  Elizabeth D Kim; Rebecca Buckley; Sarah Learman; Jessica Richard; Courtney Parke; David K Worthylake; Edward J Wojcik; Richard A Walker; Sunyoung Kim
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

4.  Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.

Authors:  Jinxia Deng; Tino Sanchez; Laith Q Al-Mawsawi; Raveendra Dayam; Rosendo A Yunes; Antonio Garofalo; Michael B Bolger; Nouri Neamati
Journal:  Bioorg Med Chem       Date:  2007-04-25       Impact factor: 3.641

5.  Novel milrinone analogs of pyridine-3-carbonitrile derivatives as promising cardiotonic agents.

Authors:  Adnan A Bekhit; Azza M Baraka
Journal:  Eur J Med Chem       Date:  2005-07-22       Impact factor: 6.514

6.  Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.

Authors:  Himesh Makala; Venkatasubramanian Ulaganathan
Journal:  J Recept Signal Transduct Res       Date:  2017-10-17       Impact factor: 2.092

Review 7.  Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy.

Authors:  Mohd Fahad Ullah
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jan-Mar

8.  Novel 9-(alkylthio)-Acenaphtho[1,2-e]-1,2,4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2).

Authors:  Mohammad K Mohammadi; Omidreza Firuzi; Mehdi Khoshneviszadeh; Nima Razzaghi-Asl; Saghi Sepehri; Ramin Miri
Journal:  Daru       Date:  2014-01-06       Impact factor: 3.117

9.  In Vitro Antiplasmodial Activity and Cytotoxic Effect of (Z)-2-Benzylidene-4, 6-Dimethoxybenzofuran-3(2H)-One Derivatives.

Authors:  Ali Ramazani; Reza Hamidnezhad; Alireza Foroumadi; Seyed Abbas Mirzaei; Somayyeh Maddahi; Seyed Mehdi Hassanzadeh
Journal:  Iran J Parasitol       Date:  2016 Jul-Sep       Impact factor: 1.012

10.  Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.

Authors:  Elena González-Hernández; Rubén Aparicio; Mercedes Garayoa; M José Montero; M Ángeles Sevilla; Concepción Pérez-Melero
Journal:  Medchemcomm       Date:  2019-07-04       Impact factor: 3.597

View more
  1 in total

Review 1.  Magnetically recoverable catalysts for the preparation of pyridine derivatives: an overview.

Authors:  Ghodsi Mohammadi Ziarani; Zohreh Kheilkordi; Fatemeh Mohajer; Alireza Badiei; Rafael Luque
Journal:  RSC Adv       Date:  2021-05-13       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.